검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab |
Overview Company | Seagen / Takeda |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Large B Cell Lymphoma |
Overview Indication | Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 89.5% |
Clinical ORR | 89.5% |
Clinical PFS | 8.0 |
Clinical OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab |
Overview Company | Seagen / Takeda |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Large B Cell Lymphoma |
Overview Indication | Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 89.5% |
Clinical ORR | 89.5% |
Clinical PFS | 8.0 |
Clinical OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교